Safety of egg membrane hydrolysate as a novel food pursuant to Regulation (EU) 2015/2283

Show simple item record

dc.contributor.author EFSA Panel Dietetic Products Nutr
dc.date.accessioned 2019-02-08T07:33:01Z
dc.date.available 2019-02-08T07:33:01Z
dc.date.issued 2018-07
dc.identifier.citation EFSA Panel Dietetic Products Nutr 2018 , ' Safety of egg membrane hydrolysate as a novel food pursuant to Regulation (EU) 2015/2283 ' , EFSA Journal , vol. 16 , no. 7 , 5363 . https://doi.org/10.2903/j.efsa.2018.5363 en
dc.identifier.issn 1831-4732
dc.identifier.other PURE: 121748726
dc.identifier.other PURE UUID: 173c3fb9-e094-479d-a2ec-8fbb962be851
dc.identifier.other WOS: 000441351400043
dc.identifier.other ORCID: /0000-0002-9930-4009/work/53825684
dc.identifier.uri http://hdl.handle.net/10138/298800
dc.description.abstract Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver a scientific opinion on egg membrane hydrolysate as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is a water-soluble hydrolysate of egg membrane, produced by alkaline treatment of the thin layer lining the shells of chicken eggs. The main constituents of the NF are elastin, collagen and glycosaminoglycans. The information provided on the production process, batch-to-batch variability, composition and specifications of the NF is sufficient and does not raise safety concerns. The NF is proposed to be used as a food supplement for adults, at a maximum daily amount of 450 mg. The consumption of the NF is not nutritionally disadvantageous. One human study, which was not designed for safety but included a number of endpoints pertaining to safety, did not raise safety concerns. The Panel considers that taking into account the information provided and considering the nature, the source and the production process of the NF, there are no safety concerns for the NF at the proposed conditions of use. The Panel concludes that the NF, egg membrane hydrolysate, is safe as a food supplement at a dose of 450 mg/day. The target population for the NF is the general adult population. (C) 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority. en
dc.format.extent 13
dc.language.iso eng
dc.relation.ispartof EFSA Journal
dc.rights en
dc.subject egg membrane hydrolysate en
dc.subject novel food en
dc.subject safety en
dc.subject MUTAGENICITY TEST en
dc.subject 416 Food Science en
dc.title Safety of egg membrane hydrolysate as a novel food pursuant to Regulation (EU) 2015/2283 en
dc.type Article
dc.description.version Peer reviewed
dc.identifier.doi https://doi.org/10.2903/j.efsa.2018.5363
dc.type.uri info:eu-repo/semantics/other
dc.type.uri info:eu-repo/semantics/publishedVersion
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl

Files in this item

Total number of downloads: Loading...

Files Size Format View
Panel_et_al_2018_EFSA_Journal_.pdf 1.357Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record